To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Tolvaptan (INN), also known as OPC-41061, is a selective, competitive arginine vasopressin receptor 2 antagonist under investigation as a potential treatment for fluid retention and hyponatremia (low blood sodium levels) associated with congestive heart failure. Tolvaptan is also in fast-track clinical trials  for treatment of polycystic kidney disease.
Additional recommended knowledge
In a 2004 trial, tolvaptan, when administered with traditional diuretics, was noted to increase excretion of excess fluids and improve blood sodium levels in patients with heart failure without producing side effects such as hypotension (low blood pressure) or hypokalemia (decreased blood levels of potassium) and without having an adverse effect on kidney function.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Tolvaptan". A list of authors is available in Wikipedia.|